Designing Drug Development Programs for Reimbursement Success
Download the guide to learn how model-informed drug development, QSP, and MBMA help align with…
CertaraMay 7, 2026
Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome
Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome
A newly approved RNA interference (RNAi) therapy lowers harmful triglyceride (TG) levels in patients with…
CertaraMay 7, 2026
Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation
This study evaluated how the leukemia drug ziftomenib behaves in the body and whether different…
CertaraMay 7, 2026
Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies
Population pharmacokinetic (PopPK) and exposure-response modeling were used to support the clinical development of nemtabrutinib,…
CertaraMay 7, 2026
Understanding quantitative effects of anti-amyloid therapies on tau biomarkers and functional outcome
QSP modeling reveals how anti-amyloid therapies impact tau biomarkers and cognitive outcomes in Alzheimer’s disease.
CertaraMay 4, 2026
Modeling CAR-T Outcomes in Multiple Myeloma
Learn how QSP modeling predicts CAR-T therapy outcomes, identifies patient-specific response drivers, and supports multi-antigen…
CertaraMay 4, 2026
Modeling T-cell Exhaustion in Immunotherapy
Discover how QSP modeling predicts T-cell exhaustion, relapse risk, and optimal dosing strategies for T-cell…
CertaraMay 4, 2026
Modeling Hematopoiesis in MDS and AML with QSP
Discover a mechanistic QSP platform model of hematopoiesis to evaluate therapies in MDS and AML,…
CertaraMay 1, 2026
IO Simulator: A QSP Platform for Immuno-Oncology
This poster showcases how IO Simulator predicts immunotherapy response and supports combination design and biomarker…
CertaraApril 30, 2026
